Medical absorable haemostatic material for osteal wounds and method for producing

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is a medical absorbable haemostatic and wound healing material for osteal wounds and a method for producing it. The absorbable haemostatic material for osteal wounds contains 40-95% of a primary material and 5-60% of an auxiliary on the basis of weight percentage, wherein the primary material contains an oligosaccharide, a polysaccharide or a mixture of the oligosaccharide and polysaccharide, while the auxiliary contains (1) one or more polyatomic alcohols, (2) one or more emulsifiers. The method for producing the absorbable haemostatic and wound healing material for osteal wounds consists of the following stages involving mixing the primary material and auxiliary in the pre-set amounts by chemical mixture and preparation of the mixture at the stage of latex, and cooling to form a solid piece, packaging and sterilising.

EFFECT: material is degradable in the body and promotes osteal wound healing.

7 cl, 4 tbl, 9 ex

 

Area of technology

The invention relates to the field of medical technology and, in particular, to absorbable hemostatic and wound-healing material for bone wounds and a method thereof.

Prior art

Medical sterile bone wax is an important auxiliary material for stopping bleeding from cancellous bone during orthopaedic surgery, thoracic surgery and neurological operations, thanks to its cementing action based on its unique hardness, stiffness, and viscosity. Currently, many types of bone wax are made by the hospitals themselves, while they do not correspond to any single formula or standard, and these types of bone wax are made mainly of beeswax and vaseline; beeswax, refined sesame oil and salicylic acid; and beeswax, peanut oil and aspirin, and the like. Most of these types of bone wax is not desired hardness, stiffness or viscosity, and they always have a weak hemostatic effect. The main types of bone wax is currently available for purchase in China, include medical bone wax, provided by the American company Johnson & Johnson, and medical sterile bone wax (Pathe�t China No. 00110393.8), developed by the Central hospital of Shenyang military region in China, the latter was approved by SFDA in 2003, Although they're all independently produced bone wax, bone wax, manufactured by Johnson & Johnson, and bone wax, developed by the Central hospital of Shenyang military region, can stop the bleeding, these types of bone wax resist degradation and remain in the body in the form of a persistent foreign substance, and in the aspect of inability to the decomposition there is no significant difference between these two types of bone wax and conventional bone wax, therefore, these non-degradable materials can be caused by nesrastanii, bacterial infection, rejection and other complications.

In China patent No. 200610093091.3 disclosed water-soluble bone wax and the method thereof, comprising a copolymer obtained by copolymerization of polyoxyethylene and polyoxypropylene, and an ester of sorbitol and fatty acids as an emulsifier, characterized in that the dissolution and removal of a copolymer of polyoxyethylene and polyoxypropylene in the body is enhanced by improving the solubility of bone wax. However, the application of bone wax in the body still occurring reaction to a foreign body, and the rate of decomposition nor very�Kaya, resulting in a prolonged period of decomposition.

In China patent No. 200510035251.4 disclosed medical hemostatic material, which can replace bone wax, and the method thereof comprises mixing in the melt of the base material and an adjuvant, wherein the core material is obtained by polycondensation in the melt of the copolymer/mixture of low molecular weight poly-DL-milk acid, or poly-L-milk acid or polyglycol acids, and auxiliary means includes polyetherdiol, polyetherdiol, high molecular weight polylactic acid, high molecular weight copolymer of glycolide and lactide, high molecular weight copolymer of caprolactone and lactide or high molecular weight copolymer of caprolactone and glycolide. In the hemostatic material of high molecular weight polymers are used as starting materials, which can resist decay and be absorbed by humans, however, requires a longer period of decomposition.

In German patent No. 3229540.5 is disclosed a method of producing absorbable bone wax, and types of bone wax contain oligomers of polyesters of hydroxycarboxylic acids and have an average molecular weight ranging from about 200 to 1500. According to this patent for a regulation of the average molecular weight oligomers slo�tion of polyesters can be used monofunctional group and/or difunctional hydroxides, or carboxyl groups or anhydrides of carboxylic acids, and/or aminoguanidine. The resulting bone wax is characterized by low elasticity and versatility, in addition, unreacted monomers in the wax can stay in the body, which can cause relatively intense irritation of the tissues of the person.

In U.S. patent No. 5143730 is disclosed a method of producing absorbable bone wax, in this method, low molecular weight polyglycol acid or low molecular weight polylactic acid is reacted with equimolar amounts of calcium carbonate at high temperature with receiving polyglycolide calcium or polylactate calcium, then the hydroxyapatite is added to the above reaction system and obtaining as a result of bone wax and bone wax, obtained in this way are characterized by a long period of decomposition in the body, besides, despite the fact that hydroxyapatite showed good biocompatibility in the body, it is a material that is not amenable to decomposition.

Absorbable biological hemostatic material Arista™ AH® (absorbable surgical hemostatic agent, Medafor Inc., USA) was studied in the clinical study of its potential use as a replacement for bone wax. So to�to this product is derived from plant polysaccharides, its decomposition in the body is fast, and there's no immune response or reaction to a foreign body, therefore it is highly secured hemostatic agent for clinical use and is suitable hemostatic agent with excellent hemostatic effect. However, since Arista™ AH® is in powder form, when you stop the bleeding on damaged cancellous bone may happen that to stop the bleeding will be very difficult, if the bone is vertical or arcuate, because a large amount of powder may crumble under the force of gravity.

Brief description of the invention

In order to solve the problem with the existing bone wax, which is not amenable to decomposition in the human body or the animal body, and, thus, impairs healing, the aim of the present invention, therefore, is the provision of hemostatic and wound-healing material for bone wounds, with the material according to the present invention fully susceptible to decomposition in the body and promotes healing of bone tissue, in addition, it can act as a replacement for bone wax, so the usual steps doctors during operations will not change.

Another objective of the present invention is that�s to provide a method of producing a medical absorbable hemostatic and wound-healing material for bone wounds.

The present invention provides the following technical solution to achieve the above objectives.

Medical absorbable hemostatic material for bone wounds containing 40-95% of the base material and 5-60% auxiliary means on the basis of the percentage content by weight of

where the basic material is an oligosaccharide, polysaccharide or a mixture of oligosaccharide and polysaccharide,

and auxiliary means includes

(1) one or more polyhydric alcohols, and

(2) one or more vegetable oils, and

(3) one or more emulsifying agents.

Preferably, the base material of the present invention is a mixture of the oligosaccharide and the polysaccharide or polysaccharide.

Preferably, an adjuvant includes

(1) one polyhydric alcohol, and

(2) one vegetable oil, and

(3) one emulsifying agent.

A mixture of oligosaccharide and polysaccharide contains 10-90% of the oligosaccharide and 10-90% of polysaccharide based on the percentage content by weight.

Oligosaccharide selected from the group comprising maltose, isomaltose, glycosylamines, soy sugar, galactose, fructose, sucrose, xylose, maltitol obtained by hydrogenation reactions, soy sugar alcohol obtained by hydrogenation reactions, galactitol obtained by re�of CCI hydrogenation, fructose alcohol obtained by hydrogenation reactions, sucrose alcohol obtained by hydrogenation reactions, and xylitol, obtained by hydrogenation reactions; preferably, the oligosaccharide is selected from the group comprising maltose, glycosylamines, soy sugar, galactose, fructose, sucrose and xylose; wherein the oligosaccharide is characterized by a molecular weight in the range 160-20000 and the viscosity value in the range of 50-700 mm G. at room temperature.

Polysaccharide selected from the group comprising carboxymethyl cellulose, carboxymethylcel, carboxylmethylcellulose, hydroxypropylmethyl, pre-castelsangiovanni starch, crosslinked carboxymethylcellulose, pharmaceutically acceptable starch, dextrin and a derivative of dextrin, and a derivative of dextrin comprises alpha-cyclodextrin, beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin, carboxymethyl-beta-cyclodextrin, sulfobutyl ether β-cyclodextrin, gamma-cyclodextrin; preferably, the polysaccharide is selected from the group comprising carboxymethyl cellulose, carboxymethylcel, carboxylmethylcellulose, hydroxypropylmethyl, pre-castelsangiovanni starch, crosslinked carboxymethylcellulose, pharmaceutically acceptable starch, dextrin; moreover, the polysaccharide is characterized by mo�colardyn weight in the range of 10000-1000000 and water absorption index of more than 5, as well as the viscosity value in the range of 10-300 mm G. at room temperature.

Auxiliary means includes 30-70% of a polyhydric alcohol, 20-60% of vegetable oil, and 1-10% of an emulsifying substances on the basis of the percentage content by weight; and polyhydric alcohol includes at least one selected from medical grade glycerin and propylene glycol; vegetable oil includes at least one selected from the group comprising olive oil, soybean oil, hydrogenated soybean oil, hydrogenated castor oil and refined corn oil; and emulsifying substance includes at least one selected from the group comprising soy phospholipid, Tween, Polysorbate and sucrose stearate.

Absorbable hemostatic material for bone wounds characterized by a bond strength ≥0.08 MPa, the bond strength when immersed in water ≥0.03 MPa and water absorption value ≥0.5 ml/g.

Preferably, the absorbable hemostatic material for bone wounds characterized by a bond strength ≥0,16 MPa, the bond strength when immersed in water ≥0.06 MPa and water absorption value ≥2.0 ml/g.

Most preferably, the absorbable hemostatic material for bone wounds characterized by a bond strength ≥0,19 MPa, the bond strength when immersed in water ≥0,16 MPa and the amount absorbed�water I ≥6.0 ml/g.

An adjuvant of the present invention includes polyhydric alcohol, vegetable oil and emulsifying substance, wherein the polyhydric alcohol is easily soluble in water, while vegetable oil is insoluble in water, thus, the hemostatic material exhibits waterproofness and eventually dissolves, the water resistance of the hemostatic material can be adjusted by the ratio of polyhydric alcohol and vegetable oil in the material. Because the mixture of polyhydric alcohol and vegetable oil has a low stability, then to the mixture you can add a certain amount of emulsifying substance, followed by stirring for the formation of chemical bonds between the polyhydric alcohol and vegetable oil, in this way greatly increases the stability of the hemostatic material.

A method of producing a medical absorbable hemostatic material for bone wounds includes the stages on which mix the main material and auxiliary means in predetermined quantities by chemical blending and mixing stage in latex, cooled with the formation of a solid piece, packaged and sterilized; and mixing the main material and auxiliary means carried out at a temperature from 40°C �about 80°C.

In the above-described method, chemical mixing and preparation of the mixture in the stage of latex include the stages on which:

(1) pre-treated base material: washed polysaccharide solvent followed by a drying process to remove impurities and microorganisms from the polysaccharide and dissolved oligosaccharide with a subsequent filtering process to remove impurities and microorganisms from the oligosaccharide;

(2) is placed a predetermined number of auxiliary means in the reaction vessel, the reaction vessel is tightly closed and evacuated, heated adjuvant to a temperature from 30°C to 50°C and maintain the temperature, mix adjuvant for 0.5-2 hours;

(3) put the specified amount of the basic material in the reaction vessel, the reaction vessel is tightly sealed and vacuumized, the mixture was heated in the reaction vessel to a temperature of from 40°C to 80°C and maintain the temperature, the mixture was stirred for 2-6 hours;

(4) pour the mixture from the reaction vessel into the casting mold, immediately put the form in conditions with temperatures ranging from 0°C to 4°C, cooled for 0.5 to 2 hours to give product as a solid piece;

(5) pack the product, followed by sterilization by radiation or oxirane.

In the way described above STE�tier dilution in the reaction vessel after the processes of vacuum ranges from 10 kPa to 30 kPa. The purpose of the evacuation process is to remove bubbles in mixing the materials generated during the mixing process to mix the materials were more homogeneous, which may contribute to the improvement of various indicators of hemostatic material.

Medical absorbable hemostatic material for bone wounds of the present invention can be applied to stop bleeding from bone wounds in humans and animals, and it can be used to help heal bone wounds in humans and animals.

The hemostatic mechanism of absorbable hemostatic material for bone wounds of the present invention is as follows: the material is effective to stop bleeding due to its cementing action, based on the unique strength of the connection, in addition, the material can absorb water from the blood. Therefore, when the hemostatic material is in contact with the blood, the blood becomes concentrated, which leads to aggregation of platelets, red blood cells and proteins of blood coagulation (such as thrombin and fibrinogen), thereby accelerating the natural process of blood clotting, and a quick stop bleeding also leads to a favourable effect.

In the hemostatic material of infusion�him to the invention the core material, and auxiliary means can easily succumb to decomposition in humans or animals, and the resulting decomposition products are absorbed and metabolized by organisms without residues or toxic side effects, depending on the dose and where the absorption of hemostatic material usually takes several weeks.

When compared with the prior art the advantages of the medical absorbable hemostatic material for bone wounds of the present invention are as follows.

Medical absorbable hemostatic material for bone wounds of the present invention is in the form of a solid piece, which simplifies the application, and it has a beneficial effect on hemostasis due to its optimal hardness, stiffness and viscosity, it can also lead to blood concentration and aggregation of platelets, red blood cells and proteins of blood clotting, thereby accelerating the natural process of blood clotting, which leads to a fast stop the bleeding; however, the material is biodegradable in humans, and the decomposition products do not have toxic side effects on the organisms, thus avoiding the cleft, BAC�ilinykh infections of rejections and other complications that can be caused by the use of conventional hemostatic medicines for damaged bones, whereby the material will not irritate human tissue, and it will be highly secured for use. Moreover, as the main material and auxiliary means are widely used worldwide pharmaceutical fillers, they are characterized by high safety, good biocompatibility, low cost, and methods for their preparation are simple, thus, the hemostatic material of the present invention is characterized by confirmed safety and value to assist in clinical practice.

Detailed description of preferred embodiments of the invention

The features of the present invention will be fully understood and taken into account proceeding from the following detailed description in combination with the variants of implementation. While preferred embodiments of the present invention will be described below, these options do not limit the implementation scope of the present invention.

EXAMPLE 1

The carboxymethyl cellulose was washed with alcohol followed by drying to obtain a powder, maltose was dissolved in distilled water, followed �altropane, and the filtrate concentrated to give syrup malt syrup, containing ≥75% by weight of maltose dissolved.

In the reaction vessel was placed 23 g medical of glycerol, 3 g Tween-80 and 10 g of olive oil, then the reaction vessel was tightly closed and was evacuated to a degree of vacuum of 10 kPa, and the mixture in the reaction vessel heated to a temperature of 50°C, maintained temperature, and the mixture was stirred for 30 minutes; the reaction vessel was placed malt syrup syrup containing 38 g of carboxymethyl cellulose and 26 g of maltose, then the reaction vessel was tightly closed and vacuumed, the mixture in the reaction vessel heated to a temperature of 80°C and maintained a degree of vacuum of 10 kPa, the mixture is then continuously stirred at low speed for 2 hours. Viscous liquid from the reaction vessel was poured into a Teflon form, and this form immediately placed in a freezer at 4°C, and the form is cooled within 120 minutes. Thus, received the product in a solid piece (sample A), which is optional formable and has a certain mechanical strength. Ultimately, the product tightly closed and Packed, followed by sterilization by radiation.

EXAMPLE 2

Oxypropylated starch washed with alcohol followed by drying to obtain a powder, sucrose races�answered in distilled water, followed by filtration to remove impurities, and the filtrate dried to produce powder. In the reaction vessel was placed 12 g of glycerol, 0.5 g of Polysorbate and 7.5 g of refined corn oil, then the reaction vessel was tightly closed and was evacuated to a degree of vacuum of 20 kPa, and the mixture in the reaction vessel heated to a temperature of 30°C, maintained temperature, and the mixture was stirred for 120 minutes; in the reaction vessel was placed 63 g hydroxypropylmethyl and 17 g of sucrose, and then the reaction vessel was tightly closed and vacuumed, the mixture in the reaction vessel heated to a temperature of 40°C and maintained a degree of vacuum of 20 kPa, the mixture is then continuously stirred at low speed for 6 hours. Viscous liquid from the reaction vessel was poured into a Teflon form, and this form immediately placed in a freezer with a temperature of 2°C, and the form is cooled within 90 minutes. Thus, received the product in a solid piece (sample B), which is optional formable and has a certain mechanical strength. Ultimately, the product tightly closed and Packed, followed by sterilization by oxirane.

EXAMPLE 3

Carboxymethylcel washed with alcohol followed by drying to obtain powder. To a reaction vessel were placed 31 g of glycerol, 2 g of Tween-80 and 9 g of soybean oil, then the reaction vessel is tightly closed�Lee and was evacuated to a degree of vacuum of 30 kPa, moreover, the mixture in the reaction vessel heated to a temperature of 30°C, maintained temperature, and the mixture was stirred for 60 minutes; in the reaction vessel was placed 58 g carboxymethylamino, then the reaction vessel was tightly closed and was evacuated, and the mixture in the reaction vessel heated to a temperature of 50°C and maintained a degree of vacuum of 30 kPa, the mixture is then continuously stirred at low speed for about 4.5 hours. Viscous liquid from the reaction vessel was poured into a Teflon form, and this form immediately placed in a freezer with temperature 0°C, and the form was cooled for 30 minutes. Thus, received the product in a solid piece (sample C), which is optional formable and has a certain mechanical strength. Ultimately, the product tightly closed and Packed, followed by sterilization by oxirane.

EXAMPLE 4

Fructose dissolved in distilled water, followed by filtration to remove impurities and the filtrate is dried to produce powder. In the reaction vessel was placed 15 g of glycerol, 1 g of Polysorbate and 7 g of hydrogenated castor oil, then the reaction vessel was tightly closed and was evacuated to a degree of vacuum of 30 kPa, and the mixture in the reaction vessel heated to a temperature of 50°C, maintained temperature and stirred with�ect for 30 minutes; in the reaction vessel was placed 77 g of fructose, then the reaction vessel was tightly closed and vacuumed, the mixture in the reaction vessel cooled to a temperature of 40°C and maintained a degree of vacuum of 30 kPa, the mixture is then continuously stirred at low speed for 1.5 hours. Viscous liquid from the reaction vessel was poured into a Teflon form, and this form immediately placed in a freezer at 4°C, and the form is cooled within 120 minutes. Thus, received the product in a solid piece (sample D), which is optional formable and has a certain mechanical strength. Ultimately, the product tightly closed and Packed, followed by sterilization by radiation.

EXAMPLE 5

Pre-castelsangiovanni starch washed with alcohol followed by drying to obtain a powder, maltose was dissolved in distilled water, followed by filtration, and the filtrate was concentrated to obtain a syrup malt syrup, containing ≥75% by weight of maltose dissolved. To a reaction vessel were placed 16 g of glycerol, 1 g Tween-80 and 10 g of refined corn oil, then the reaction vessel was tightly closed and was evacuated to a degree of vacuum of 10 kPa, and the mixture in the reaction vessel heated to a temperature of 30°C, maintained temperature and stirred cm�camping for 30 minutes; in the reaction vessel was placed 63 g pre-castelsilano starch and malt syrup syrup containing 10 g of maltose, then the reaction vessel was tightly closed and was evacuated, and the mixture in the reaction vessel heated to a temperature of 50°C and maintained a degree of vacuum of 10 kPa, then the mixture was continuously stirred at low speed for 3.5 hours. Viscous liquid from the reaction vessel was poured into a Teflon form, and this form immediately placed in a freezer at 4°C, and the form is cooled within 120 minutes. Thus, received the product in a solid piece (sample E), which is optional formable and has a certain mechanical strength. Ultimately, the product tightly closed and Packed, followed by sterilization by oxirane.

EXAMPLE 6

Dextrin is washed with alcohol followed by drying to obtain a powder, sucrose was dissolved in distilled water, followed by filtration to remove impurities and the filtrate is dried to produce powder. To a reaction vessel were placed 13 g of glycerol, 1 g of Polysorbate and 10 g of refined corn oil, then the reaction vessel was tightly closed and was evacuated to a degree of vacuum of 30 kPa, and the mixture in the reaction vessel heated to a temperature of 30°C and maintained the temperature and ne�amichevoli the mixture for 90 minutes; to a reaction vessel were placed 60 g of dextrin 16 g of sucrose, and then the reaction vessel was tightly closed and was evacuated, and the mixture in the reaction vessel heated to a temperature of 50°C and maintained a degree of vacuum of 30 kPa, the mixture is then continuously stirred at low speed for 4 hours. Viscous liquid from the reaction vessel was poured into a Teflon form, and this form immediately placed in a freezer at 4°C, and the form was cooled for 60 minutes. Thus, received the product in a solid piece (sample F), which is optional formable and has a certain mechanical strength. Ultimately, the product tightly closed and Packed, followed by sterilization by radiation.

EXAMPLE 7

Pharmaceutically acceptable starch washed with alcohol followed by drying to obtain powder. To a reaction vessel were placed 20 g of glycerin, 10 g of propylene glycol, 0.3 g of Polysorbate, 0.3 g of sucrose stearate and 29.4 g of refined corn oil, then the reaction vessel was tightly closed and was evacuated to a degree of vacuum of 30 kPa, and the mixture in the reaction vessel heated to a temperature of 30°C, maintained temperature, and the mixture was stirred for 90 minutes; the reaction vessel was placed 40 g of pharmaceutically acceptable starch, then the reaction vessel �wetland was closed and vacuumed, moreover, the mixture in the reaction vessel heated to a temperature of 50°C and maintained a degree of vacuum of 30 kPa, the mixture is then continuously stirred at low speed for 4 hours. Viscous liquid from the reaction vessel was poured into a Teflon form, and this form immediately placed in a freezer at 4°C, and the form was cooled for 60 minutes. Thus, received the product in a solid piece (sample G), which is optional formable and has a certain mechanical strength. Ultimately, the product tightly closed and Packed, followed by sterilization by radiation.

EXAMPLE 8

Oxypropylated starch washed with alcohol followed by drying to obtain a powder, sucrose was dissolved in distilled water, followed by filtration to remove impurities and the filtrate is dried to produce powder. In the reaction vessel was placed 21 g of glycerol, 3 g of Polysorbate, 3 g of refined corn oil and 3 g of olive oil, then tightly closed and was evacuated to a degree of vacuum of 30 kPa, and the mixture in the reaction vessel heated to a temperature of 30°C, maintained temperature, and the mixture was stirred for 90 minutes; the reaction vessel was placed 52 g hydroxypropylmethyl and 18 g of sucrose, and then the reaction vessel was tightly closed and vacuum�up, moreover, the mixture in the reaction vessel heated to a temperature of 50°C and maintained a degree of vacuum of 30 kPa, the mixture is then continuously stirred at low speed for 4 hours. Viscous liquid from the reaction vessel was poured into a Teflon form, and this form immediately placed in a freezer at 4°C, and the form was cooled for 60 minutes. Thus, received the product in a solid piece (sample N), which is optional formable and has a certain mechanical strength. Ultimately, the product tightly closed and Packed, followed by sterilization by radiation.

EXAMPLE 9

The carboxymethyl cellulose was washed with alcohol followed by drying to obtain a powder, maltose was dissolved in distilled water, followed by filtration, and the filtrate was concentrated to obtain a syrup malt syrup, containing ≥75% by weight of maltose dissolved.

In the reaction vessel was placed 1.5 g of medical glycerol, 0.5 g Tween-80 and 3 g of olive oil, then the reaction vessel was tightly closed and was evacuated to a degree of vacuum of 20 kPa, and the mixture in the reaction vessel heated to a temperature of 40°C, maintained temperature, and the mixture was stirred for 60 minutes; in the reaction vessel was placed malt syrup syrup containing 45 g of carboxymethyl cellulose and 50 g m�of ltsy, then the reaction vessel was tightly closed and was evacuated, and the mixture in the reaction vessel heated to a temperature of 60°C and maintained a degree of vacuum of 20 kPa, the mixture is then continuously stirred at low speed for 5 hours. Viscous liquid from the reaction vessel was poured into a Teflon form, and this form immediately placed in a freezer at 4°C, and the form is cooled within 120 minutes. Thus, received the product in a solid piece (sample I), which is optional formable and has a certain mechanical strength. Ultimately, the product tightly closed and Packed, followed by sterilization by radiation.

In the above-described embodiments, the oligosaccharide is characterized by a molecular weight in the range 160-20000 and the viscosity value in the range of 50-700 mm G. at room temperature; wherein the polysaccharide is characterized by a molecular weight in the range of 10000-1000000 and water absorption index of more than 5, and a viscosity value in the range of 10-300 mm G. at room temperature.

EXPERIMENT 1

The mark I
Table 1
The physical parameters of the different samples obtained with different methods in the examples above,
SampleAppearanceThe value of my absorption-
of water,
ml/d
Wearable-
ability to use
the NIJ
Drying time, hours/
Resistance
tion cracks
Time dissolve
rhenium,
min.
The strength of the bond,
MPa
Strength
connection when immersed in water, MPa
Sample AExcellent47Good72/Excellent490,470,31
Sample BExcellent5Excellent33/Excellent370,240,17
Sample CGood27Good20/Good210,190,16
P�both D Good0,5Excellent16/Good350,090,03
Test EExcellent4Excellent10/Good300,330,21
Sample FGood3,5Excellent36/Excellent200,220,14
Sample GExcellent15Excellent21/Good250,080,03
Sample HExcellent10Excellent30/Excellent230,280,19
Good6Good34/Excellent180,250,18
Note: assessment of appearance by homogeneity, caking and the formation of cracks in the material.

The water absorption value (ml/g): the maximum value of water absorption before the collapse of the sample pieces/weight of the sample piece.

Suitability for use: the experimenter evenly struck each sample on the surface of the plate for testing to verify in practice ease of application in order to determine the ease of use.

Drying time: the experimenter evenly struck each sample on the surface of the plates for tests to determine the time required for complete drying of the sample.

Time of dissolution (hours): experimenter loaded each sample in water at 37°C to determine the time required for dissolution of the sample.

Bond strength: according to standard test method ASTM D952 each sample was put on the bottom plate for testing of two metal plates of the machine to test materials, manufactured by Lloyd Instruments - LS1, thus the thickness of the p�NALAS 2 mm, then pushed back the upper plate for testing before full contact with the sample, then started the test, and the test speed was 0.01-0.02 mm/min; the obtained data were analyzed using software for data analysis NEXYGEN Plus to get results.

Bond strength when immersed in water: each sample was put on the top plate for testing of two metal plates of the machine to test materials, manufactured by Lloyd Instruments - LS1, thus the thickness was 2 mm, and after the upper plate for testing and the sample was immersed in water at 50 seconds, pushed the upper plate for testing so that the sample was in full contact with the bottom plate for testing, then began testing, and operating parameters and the process of data analysis were the same as above.

EXPERIMENT 2

The purpose of the experiment

The experiment was carried out to investigate the efficacy of absorbable hemostatic and wound-healing material for bone wounds of the present invention when stopping bleeding and healing of the bones of the skull of the rabbit.

Tested samples

Sample A, sample B, sample C, sample D, sample E, sample F and commercially available bone wax.

Experimental methods

Gave 24 healthy adult new Zealand rabbit (20-2,5 kg) and each of these rabbits drilled 4 damage dice then randomly distributed into 8 groups, i.e. control group, the control group sample group sample group sample group sample D, the sample group E, the group of samples F and the bone wax group, so each group had 12 damage dice. New Zealand rabbits were anestesiologi intravenous injection of a 3% solution of pentobarbital sodium (1 ml/kg), and the limbs of the rabbits were fixed on the operating table in the supine position. Did sagital scalp incision approximately 4 cm long and carefully removed the periosteum in order to reveal the parietal part of the skull. Used a drill with a diameter of 6 mm to drill two damage a round shape on both sides of the median suture of the skull, and all damage is passed through the layer of the parietal part of the skull (where the thickness of the cranial vault was the same) and did not cross the midline seam. Damage randomly coated absorbable hemostatic and wound-healing material for bone wounds of the present invention or bone wax, or anything not covered in the quality control. Used absorbable sutures to connect the periosteum and fur of the scalp during surgery, and after the imposition of sterile dressings rabbits were placed in cages for further recovery. Rabbits daily did lotrimi�ecou injection of 40 units. gentamicin for 3 days after surgery to prevent infection. The General condition of these animals was observed at intervals of a day.

During the operation, observed the effectiveness of stop bleeding various experimental materials, recorded the number of samples in which it was implemented successfully stop bleeding, and the rate of successful hemostasis appropriate material. 6 weeks after surgery, animals killed by air embolism, then examined the remains of the experimental materials in the field of application of hemostatic and wound-healing material for bone wounds of the present invention or bone wax; wherein the selected samples of the damaged bones of the skull together with the bordering part of the surrounding bone, at least 1.5 cm from the edge of the damage, and including the adjacent periosteum of the skull and the Dura. Samples of the bones of the skull fixed in 70% ethanol. The experimenter determined the assessment of bone healing, bone healing was evaluated against all damages by using the following evaluation of healing described for these groups: assessment of healing 0=no visible damage; 1=minimal visible damage; 2=moderate visible damage; 3=extensive visible damage.

RESULT�YOU

After applying the samples, the experimenter observed the process of stopping the bleeding within 1 minute, it was concluded that absorbable hemostatic and wound-healing material for bone wounds of the present invention, including all of the sample A, sample B, sample C, sample D, sample E, sample F, and bone wax, provided effective hemostasis, however, the damage inflicted on the sample D, the beginning to bleed again, and this is recorded as an unsuccessful attempt to stop the bleeding. Bleeding from lesions in the control group it was impossible to stop pressing for 1 minute. When compared with the control tested samples of the blend hemostatic material, including everything from sample A, sample B, sample C, sample D, sample E, sample F, and bone wax provided a statistically significant decrease in the volume of bleeding (p<0.01) and was characterized by a short time for bleeding to stop. Cm. table 2.

Table 2
The influence of various experimental materials to stop bleeding when applied to bleeding from the bones of the skull in rabbits
GroupInterested�the specimens, they conducted successful hemostasis/total number of samples testedThe rate of successful hemostasis, %
Control group0/120
The sample group A12**/12100
The sample group B12**/12100
The sample group C12**/12100
The sample group D11**/1291,7
The sample group E12**/12100
The sample group F12**/12100
The sample group G12**/12100
The sample group H12**/12100
Group I trials12**/12100
Group bone �Oska 12**/12100
**p<0.01 compared with the control group.

Studied the remains experimental materials all the damage, while not found any residue in the control group, the sample group B, the group of the sample, the sample group D, the group of sample E and sample group F, and in damages from a group of samples And observed a small amount of residue, whereas bone wax remained entirely in the damage of the bone wax group without any signs of decomposition. Determined the evaluation of bone healing in relation to the skull fracture 6 weeks after surgery, and the results showed that all of the group sample group sample group sample group sample D, sample E and sample F was characterized by a clearly lower ratings compared with the control (p<0,05), which indicates that these 9 samples can contribute to the healing of the bones of the skull in rabbits, while the difference between the 9 samples was not statistically significant; the distinction between the bone wax group and the control group was also not statistically significant (p>0,05). Cm. table 3.

Table 3
Residues and evaluation of bone healing in each group skull fracture rabbits
GroupThe number of residuesEvaluation of bone healing
Control group--2,11±0,86
Group sampleA small amount1,34±0,43*
The sample group BNot found1,44±0,25*
Group sampleNot found1,29±0,45*
The sample group DNot foundA 1.54±0,23*
The sample group ENot found1,36±0,23*
The sample group FNot found1,41±0,23*
The sample group GNot found1,48±0,43*
The group of samples NNot found 1,39±0,23*
Group I trialsNot found1,46±0,23*
The bone wax groupA large number of2,06±0,63
*p<0.05 compared with the control group.

EXPERIMENT 3

The aim of experiment: the purpose of the experiment was to determine the influence of the medical absorbable hemostatic and wound-healing material for bone wounds on the healing of long bones in dogs.

Experimental methods: gave 10 healthy adult dogs and each dog has drilled a total of 4 damage dice round shape in the long bones of the four limbs (i.e., one damaged bones in each limb), therefore, only provided 40 damage dice, and during the operation test, sample E and sample N absorbable hemostatic and wound-healing material for bone wounds of the present invention randomly inflicted damage, then this damage were divided into 5 groups, i.e. control group, the control group sample, the sample group E, a group of samples N and the bone wax group, on 8 damage in each group. 6 weeks after surgery, animals killed, and about�the samples thigh injury picked together with the bordering part of the surrounding bone, at least 1.5 cm from the edge of the damage, then the samples recorded, poured paraffin, cut with conventional methods, studied and photographed with the use of fluorescence microscopy under UV light. Tetracycline and calcein can contact with newly formed bone at the interface bone/osteoid (demineralizovannaja bone), where it finds the linear fluorescence, therefore, calculated the amount of bone formed during the 6-week period of time, by measuring the distance between two fluorescently labeled lines to determine the level of oppozitsii minerals (MAR), the indicator of the activity of osteoblasts, i.e. the speed of bone formation.

MAR=The distance between two fluorescently labeled lines, µm
The time interval between the introduction of two markers

The results of the experiment: the results of the level of oppozitsii minerals specified 6 weeks after surgery showed that all of the group sample group sample E and sample N were characterized by statistically significantly higher levels of oppozitsii minerals compared with the control group, and the bone wax group (p<, 05). Cm. table 4.

Table 4
The level of oppozitsii minerals in each group
GroupThe level of oppozitsii minerals, µm/day
Control group2,02±0,34
Group sample3,88±0,84*#
The sample group E3,94±0,94*#
The group of samples N3,52±0,98*#
The bone wax group1,96±0,48
*p<0.05 compared with control, #p<0.05 compared with bone wax group.

1. Medical absorbable hemostatic material for bone wounds, characterized in that it contains 40-95% of the base material and 5-60% auxiliary means on the basis of the percentage content by weight;
where the basic material is an oligosaccharide selected from maltose, fructose and sucrose, polysaccharide, selected from carboxymethyl cellulose, hydroxypropylmethyl, carboxymethylamino, pre-castelsilano�on starch, of dextrin and pharmaceutically acceptable starch, or a mixture of oligosaccharide and polysaccharide;
and auxiliary means includes:
(1) 30-70% by weight of one or more polyols selected from glycerine and propylene glycol,
(2) 20-60% by weight of one or more vegetable oils selected from corn oil, soybean oil, castor oil and olive oil, and
(3) 1-10% by weight of one or more emulsifying agents selected from Polysorbate and Tween-80.

2. Medical absorbable hemostatic material for bone wounds according to claim 1, characterized in that the mixture of oligosaccharide and polysaccharide contains 10-90% of the oligosaccharide and 10-90% of polysaccharide based on the percentage content by weight.

3. Medical absorbable hemostatic material for bone wounds according to claim 1, characterized in that the absorbable hemostatic material for bone wounds characterized by the strength of the relation0.08 MPa, the bond strength when immersed in water0.03 MPa and water absorption value0.5 ml/g.

4. A method of producing a medical absorbable hemostatic material for bone wounds according to any of claims. 1-3, including this�s, which mix the main material and auxiliary means in predetermined quantities by chemical blending and mixing stage in latex, cooled with the formation of a solid piece, packaged and sterilized, wherein the mixing of the base material and additives is carried out at a temperature from 40°C to 80°C.

5. A method of producing a medical absorbable hemostatic material for bone wounds according to claim 4, characterized in that the chemical mixing and preparation of the mixture in the stage of latex include the stages at which:
(1) pre-treated base material: washed polysaccharide solvent followed by a drying process to remove impurities and microorganisms from the polysaccharide and dissolved oligosaccharide with a subsequent filtering process to remove impurities and microorganisms from the oligosaccharide;
(2) is placed a predetermined number of auxiliary means in the reaction vessel, the reaction vessel is tightly closed and evacuated, heated adjuvant to a temperature from 30°C to 50°C and maintain the temperature, mix adjuvant for 0.5-2 hours;
(3) put the specified amount of the basic material in the reaction vessel, the reaction vessel is tightly sealed and vacuumized, the mixture was heated at re�Clennam vessel to a temperature of from 40°C to 80°C and maintain the temperature, the mixture was stirred for 2-6 hours;
(4) pour the mixture from the reaction vessel into the casting mold, immediately put the form in conditions with temperatures ranging from 0°C to 4°C, cooled for 0.5 to 2 hours to give product as a solid piece.
(5) pack the product, followed by sterilization by radiation or oxirane.

6. A method of producing a medical absorbable hemostatic material for bone wounds according to claim 5, characterized in that the degree of vacuum in the reaction vessel after the processes of vacuum ranges from 10 kPa to 30 kPa.

7. The use of a medical absorbable hemostatic material for bone wounds according to any of claims. 1-3 for control of bleeding from bone wounds in humans and animals and to facilitate the healing of bone wounds in humans and animals.



 

Same patents:

FIELD: veterinary medicine.

SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injection is added to the lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin monomer at a concentration of 11 mg/ml and urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. At that the dose of fibrin-monomer is 0.25 mg/kg.

EFFECT: method is highly effective the prevention of bleeding caused by the use of streptokinase, prior to surgical interferences.

1 ex, 2 dwg

FIELD: veterinary medicine.

SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injections is added to lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin-monomer at a concentration of 11 mg/ml and the urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. The dose of fibrin-monomer is 0.25 mg/kg.

EFFECT: method is highly effective for prevention of bleeding caused by the use of dabigatran etexilate in the experiment.

2 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with pharmaceutical composition, containing suspension, which includes mixture of hydrophobic medium and solid form, where solid form contains therapeutically effective quantity of octreotide and, at least, one salt of fatty acid with medium chain length, which has chain length from 6 to 14 carbon atoms, and matrix-forming polymer, selected from dextran and polyvinylpyrrolidone (PVP), with salt of fatty acid with medium chain length being present in composition in amount of 10% by weight or more. Group of inventions also deals with capsule, containing said composition, intended for peroral introduction; method of obtaining said pharmaceutical composition.

EFFECT: group of inventions relates to improvement of octreotide bioavailability.

100 cl, 39 ex, 10 dwg, 45 tbl

FIELD: medicine.

SUBSTANCE: medication based on tripeptide Ac-Ala-Phe-Lys-Pip·AcOH or its pharmaceutically acceptable salts is applied. The claimed medication can be made in the form of a solution, gel, plate or sponge.

EFFECT: application of the said medication makes it possible to considerably reduce the volume of haemorrhage and reduce the time of bleeding stopping due to high anti-plasmin activity of the tripeptide Ac-Ala-Phe-Lys-Pip·AcOH with the absence of side effects.

2 cl, 8 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: wound canal is packed with a preparation of recovered oxygenated cellulose. Thereafter in an entrance wound, the preparation is exposed to 2 cycles of cryotherapy with liquid nitrogen at a temperature of minus 196°C for 1-2 minutes until an ice crust is formed on the wound surface.

EFFECT: method provides excluding the possibility of bleeding and bile flowing from an inner surface of stab wounds, reducing a risk of recurrent bleedings, formation of liver haematomas postoperatively.

3 dwg, 2 tbl, 2 ex

Haemostatic agent // 2545991

FIELD: medicine.

SUBSTANCE: invention relates to medicine and veterinary and is intended for the acceleration of stopping bleeding in case of injury to blood vessels in traumas and wounds. A haemostatic agent contains 3-20 wt % of a polysaccharide, where the polysaccharide is represented by chitosan and/or starch, 0.1-2 wt % of calcium chloride and a 0.5-5% water solution of succinic or hydrochloric acid - the remaining part.

EFFECT: accelerating the initiation of the thrombus-forming process and enhancement of the regenerative ability of tissues in the area of wounds of different aetiology.

1 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutically acceptable salts specified in a group consisting of sodium salt, lithium salt, potassium salt, calcium salt, magnesium salt, arginine salt, lysine salt, methanamine salt, dimethylamine salt, trimethylamine salt, ethylamine salt, diethylaminte salt, triethylamine salt, ethanolamine salt, piperazine salt, dibenzylethylene diamine salt, methyl glucamine salt, tromethamine salt, quaternary tetramethylammonium salt, quaternary tetraethylammonium salt and choline salt, bicyclosubstituted azopyrazole derivatives of general formula

.

The invention also refers to a method for preparing them, a pharmaceutical composition containing them, and using them as a therapeutic agent, particularly as thrombopoietin (TPO) mimetics, using them as TPO agonists. In general formula (I), Het is specified in a group consisting of phenyl, furanyl and thienyl; each R1, R2, R3 andR4 are independently specified in a group consisting of hydrogen and alkyl; n is equal to 0, 1 or 2.

EFFECT: improving the pharmokinetic properties of the compound of formula (I) ensured by better solubility.

19 cl, 1 tbl, 25 ex

FIELD: biotechnology.

SUBSTANCE: bispecific antibody is proposed, that binds to both the blood coagulation factor IX/activated blood coagulation factor IX and with the blood coagulation factor X, and functionally replaces the function of blood coagulation factor VIII. The nucleic acid is considered, encoding the antibody of the invention, a vector, a cell and a method of producing the antibody, and also a pharmaceutical composition and a kit for use in the method of preventing and/or treating bleeding or diseases associated with or caused by bleeding.

EFFECT: invention may find further application in the treatment of diseases associated with impaired blood clotting.

16 cl, 2 ex, 6 dwg

FIELD: chemistry.

SUBSTANCE: claimed is bispecific antibody, which is bound with both blood coagulation factor IX/activated blood coagulation factor IX and with blood coagulation factor X and functionally replaced function of blood coagulation factor VIII. Described are nucleic acid, coding antibody by invention, vector, cell and method of obtaining antibody, as well as pharmaceutical composition and set for application in method of prevention and/or treatment of bleeding or diseases, associated with or induced by bleeding.

EFFECT: invention can be applied in therapy of diseases, associated with blood coagulation disorders.

16 cl, 2 ex, 6 dwg

FIELD: medicine.

SUBSTANCE: antiproteolytic preparation Ambene in a dose of 50-250 mg is introduced intravenously by the stream infusion for at least three days every 3-4 hours in a combination with heparin. Heparin is introduced subcutaneously is a dose of 250 units 4 times a day.

EFFECT: effective treatment of endogenous intoxication syndrome caused by proteolysis by blocking fibrinolysis and enhancing the detoxifying and anti-inflammatory action of Ambene.

2 tbl, 2 ex

Echogenic sleeve // 2556570

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment, namely to means with increased echogenicity for obtaining ultrasonic images. Device contains intervention device, image of which must be received by means of ultrasound, and echogenic polymer sleeve, located near intervention device and containing biocompatible deformable membrane, which covers at least part of intervention device. Topography of echogenic polymer sleeve is adjustable by means of its axial compression, which changes length of echogenic polymer sleeve relative to intervention device and forms riffles on biocompatible deformable membrane, riffles are visible for ultrasound and increase echogenicity of intervention device. Method of increasing echogenicity includes placement of biocompatible membrane near intervention device and compression of sleeve along axis to change its length and form riffles on biocompatible deformable membrane. In second version of device implementation mechanical deformation of echogenic polymer sleeve changes its thickness and forms riffles on biocompatible deformable membrane.

EFFECT: application of invention improves visibility of objects in ultrasound.

16 cl, 4 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment, namely to means with higher echogenicity for obtaining ultrasonic images. Intervention device contains intervention device, for which obtained is ultrasonic image, which has external surface, containing one or more topographic irregularities of in other cases smooth surface of intervention device and polymer film, which is in tight contact with external surface and closed at least part of one or more topographic irregularities, with tension of polymer film and resonance characteristic of polymer film are adjustable. In method of increasing echogenicity one or more topographic irregularities of in other cases smooth external surface of intervention film is (are) formed, with polymer film being placed in tight contact with external surface, with tension of polymer film being adjustable. Echogenic response of intervention device is regulated by means of device visualisation of device and regulation of polymer film tension, with adjustment of tension changing resonance characteristics of polymer film, covering one or more topographic irregularities.

EFFECT: application of invention makes it possible to improve visibility of objects in ultrasound.

13 cl, 4 dwg

FIELD: medicine.

SUBSTANCE: tissue regeneration or healing is stimulated when using a structure comprising a multilayer plate of a collagen membrane material, which contains a lamellated barrier material of pure collagen prepared of a natural collagen tissue; the lamellated barrier material containing a barrier layer with an outer smooth barrier surface and a fibre surface, which is opposite the outer smooth barrier surface. The structure additionally contains a matrix layer of a collagen sponge material adjoining the fibre surface.

EFFECT: matrix layer of the collagen sponge material is absorbed by an individual's body at a higher rate, than the lamellated barrier material.

20 cl, 3 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to the application of a solid medicinal product, which is heated under the impact of an alternating magnetic field, for further therapeutic treatment after surgical ablation of tumours and cancerous ulcers. The medicinal product represents a surgical implant, presented in the form of a physiologically acceptable fabric, sponge or film. The medicinal product contains magnetic particles, which generate heat when excited by an impact of the alternating magnetic field, and in this way, heat the medicinal product.

EFFECT: invention ensures considerable improvement of further treatment after operation on cancerous tumour in comparison with chemotherapy.

21 cl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely a method for preparing a filling material for plastic surgery and instrumental cosmetology. A method for preparing the filling material for plastic surgery and instrumental cosmetology consisting in the fact that sodium hyaluronate is prepared of cock's combs; a fraction of molecular weight 1000-2000 kDa is recovered; then sodium cations are substituted by cetylpyridinium cations; prepared hyaluronate ammonium salt is dissolved in an aprotonic solvent to produce internal esters; modified sodium hyaluronate is recovered by adding aqueous sodium chloride; sodium hyaluronate is deposited in acetone, dried and sterilised; thereafter the modified material is processed in a physiologically compatible aqueous solution to complete swelling and mechanically ground. The filling material for plastic surgery and instrumental cosmetology. The method for introducing the filling material for plastic surgery and instrumental cosmetology into problem area.

EFFECT: method enables preparing the biocompatible filling material with the pre-set physical-chemical properties.

3 cl, 3 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to surgery and may be used for making external osteosynthesis implants. An osteosynthesis system comprises a piece part on an external surface of which there is a layer of a polymer film in the electret state with the layer of the polymer film made of a fusible element. The group of inventions refers to a method for making the osteosynthesis system involving preparation the layer of the polymer film on an external surface of the piece part by coating the surface of the piece system with a fine fusible polymer powder, fusion thereof on the surface of the piece part and electrostatic charging of the prepared film.

EFFECT: group of invention provides making a uniform coating of the electret layer on the surface of the piece part of the osteosynthesis system firmly attached to the surface of the piece part that enables faster fusion of bone fragments due to electric stimulation and prevented implant corrosion.

10 cl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to N-substituted monomers and polymers, methods of producing such monomers and polymers and methods for their use for different medical purposes, e.g., in medical devices. Disclosed is a polymer which contains a repeating unit of formula (I), where X1 and X2 are independently selected from Br and I; y1 and y2 are equal to zero or an integer from 1 to 4, A1 is selected from a group consisting of , , , and , R3 is selected from C1-C30 alkyl, and C1-C30 heteroalkyl, C5-C30 aryl, C6-C30 alkylaryl and C2-C30 heteroaryl; R4 is selected from H, C1-C30 alkyl and C1-C30 heteroalkyl; R1 is (A) or (B); Z is O or S; R5 and R6 are selected from -CH=CH-, -CHJ1-CHJ2- and -(CH2)a-; a equals zero or an integer from 1 to 8; J1 and J2 are independently selected from H, Br and I; Q is a group which contains 20 or more carbon atoms; Rx is selected from optionally substituted branched or straight C7-C30 alkyl and optionally substituted C6-C30 aryl; and Ry is selected from hydrogen, optionally substituted branched or straight C1-C30 alkyl and optionally substituted C6-C30 aryl. Also disclosed are versions of said polymer, methods of producing said polymers and a medical device containing the disclosed polymers. The medical device is preferably a stent.

EFFECT: disclosed polymer has improved physical and chemical properties and is suitable for use in implantable medical devices.

31 cl, 1 dwg, 2 tbl, 3 ex

Tissues adhesives // 2443435

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is a multilayer tissue adhesive sheet which contains a structure layer or a laminated plastic attached to a layer supposed to contact with tissue. The structure layer or the laminated plastic contains one or more synthetic polymers showing film-forming properties, while the tissue contact layer contains tercopolymer poly(VP-AAc-AAc(NHS)). The synthetic polymers showing film-forming properties are preferentially biodegradable polyesters, while the tissue reactive groups are most preferentially NHS-polyester groups.

EFFECT: sheet shows better flexibility and herewith keeps high adhesive strength.

26 cl, 2 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: compositions, methods and sets applied to sealing of injured tissues are described herein; the compositions are produced by combining of the first transversally cross-linked component with the second transversally cross-linked component to the effect of formation of the porous matrix with spans, and combining of the porous matrix with the hydrocarbon gel forming component applied to filling-in at least some of the spans.

EFFECT: compositions have minimal turgescing properties.

15 cl, 15 tbl, 14 dwg, 26 ex

Implants with fk506 // 2332959

FIELD: medicine.

SUBSTANCE: invention refers to implants, in particular, to intracavernous or intravascular implants, and is preferable for treatment or preventive maintenance of coronary or peripheric narrowings or occlusions of vessels, in particular, narrowings, or stenosis or restenosis respectively, preferably for prevention of restenosis which, in chemically covalent or incovalent to the bound or physically fixed form, contain FK506, to the method of their obtaining and application.

EFFECT: reduction of inflammation centres.

52 cl, 7 dwg, 10 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to a polymer composition for medical devices containing polycarbonate with a degree of polymerisation of n=200-2,000 in an amount of 100 weight fractions, a polymer additive, which is presented by polysulphon at a degree of polymerisation of n=70-150, in an amount of 5 to 40 weight fractions, a complex stabiliser, which is presented by sterically hindered phosphite in an amount of 0.045 to 1.5 weight fractions, a compatibiliser representing maleinised polypropylene in an amount of 0.025 to 5.0 weight fractions, a nanostructured additive representing carbon nanotube superconcentrate with the nanotube content of 20-40 weight fractions in butadiene oligomer with a degree of polymerisation of 6 in an amount of 0.01 to 1.0 weight fractions.

EFFECT: invention provides creating the polymer composition with high strength characteristics.

3 cl, 1 ex, 2 tbl

Up!